Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Completed · Early Phase 1

Conditions studied: Healthy Volunteers

In brief

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.

Key facts

Study ID

NCT05471609

Run by

University of Minnesota

People needed

6

Starts

2025-06-12

Expected to finish

2025-08-14

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Normal healthy
• Are 18-65 years of age
• Are not currently taking medications regularly
• Able to fast 6 hours (water allowed)

You may not qualify if…

• Pregnancy
• Inability to fast

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.